NovaBridge Biosciences (NBP) Cash from Discontinued Operations (2020 - 2024)
NovaBridge Biosciences (NBP) posted quarterly Cash from Discontinued Operations of 26460000.0 for Q3 2024, up 178.66% on a QoQ basis from 33640206.31 in Q3 2020.
NovaBridge Biosciences (NBP) Cash from Discontinued Operations (2020 - 2024) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Cash from Discontinued Operations for 2 consecutive years, with 26460000.0 the latest figure, recorded in Q3 2024.
- Quarterly Cash from Discontinued Operations changed N/A year-over-year to 26460000.0 in Q3 2024, while the trailing twelve-month figure through Dec 2025 was 26460000.0 (changed N/A YoY) and the FY2024 annual result came in at 27498000.0, up 74.95% from the prior year.
- Cash from Discontinued Operations improved to 26460000.0 in Q3 2024 per NBP's latest filing, from 33640206.31 in the prior quarter.
- Over the last five years, Cash from Discontinued Operations for NBP reached as high as 26460000.0 in Q3 2024 and fell as low as 33640206.31 in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | NovaBridge Biosciences | 389.86 Mn | 389.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 26.46 Mn |
| Sep 30, 2024 | 26.46 Mn |
| Sep 30, 2020 | -33.64 Mn |
| Sep 30, 2020 | -33.64 Mn |